India’s hospital sector is attracting billions of dollars from global private-equity investors, helping fund new hospitals, advanced medical technology and consolidation across a fragmented healthcare market. At the same time, the growing role of private capital is intensifying concerns over treatment costs, insurance coverage and affordability.
Blackstone, KKR, TPG, General Atlantic and other global investors have invested about $10 billion in Indian hospital chains over the past five years, according to EY data. Private-equity-backed operators still account for less than 5% of the country’s hospital beds, but have established a significant presence in high-value specialties such as oncology and cardiac care.
Investment drives hospital expansion
India’s shortage of healthcare infrastructure has been a major attraction for investors. The country has around 1.3 hospital beds per 1,000 people, considerably below many developed economies.
Rising demand for specialised treatment, combined with the fragmented nature of the hospital market, has created opportunities to build larger networks through acquisitions and expansion.
In 2021, policymakers identified around 600 hospital projects requiring an estimated $32 billion in investment, highlighting the scale of infrastructure needed.
Private capital has subsequently supported expansion by existing hospital groups while enabling consolidation among standalone and regional operators.
Hospital valuations and earnings rise
The financial performance of the sector has strengthened alongside investment. Crisil expects private hospitals’ revenue to grow by up to 15% in fiscal 2027, supported by higher patient volumes and an estimated increase of up to 7% in average revenue per occupied bed.
KKR’s healthcare portfolio illustrates the pace of consolidation. Its investment in Kerala-based Baby Memorial Hospital was followed by rapid expansion through acquisitions. KKR also agreed in August to acquire Swedish hospital group Medicover’s Indian operations for $1.4 billion, a transaction expected to significantly increase its hospital bed capacity in southern India.
Private-equity investors have also benefited from India’s developing capital markets, which provide opportunities to exit investments through stock-market listings and secondary share sales.
Affordability becomes a growing concern
The financial growth of private hospitals has, however, attracted increasing scrutiny from policymakers.
A parliamentary committee in August raised concerns about the growing influence of foreign capital in healthcare and the acquisition of smaller hospitals by large corporate groups. It recommended examining foreign investment rules, healthcare pricing and the possibility of a dedicated regulatory framework for hospitals.
Medical inflation has been reported at as much as 13% annually, adding to concerns about the affordability of treatment.
According to a parliamentary panel, treatment in private hospitals can cost five to 10 times more than in the public healthcare system, with significant differences reported in areas including cancer care, cardiac treatment, kidney failure and maternity services.
Hospitals and insurers clash over rising bills
The expansion of private healthcare has also increased friction between hospitals and health insurers.
Insurers argue that some hospitals are increasing treatment costs and encouraging expensive procedures, while hospital operators point to reimbursement levels and delays in insurer payments as pressures on their margins.
The disagreement has become particularly relevant as hospitals increasingly adopt robotic surgery, advanced implants and other expensive technologies.
Niva Bupa Health Insurance COO Bhabatosh Mishra has said insurers require evidence-based treatment protocols to determine whether newer procedures provide sufficient clinical benefits compared with conventional treatments.
Patients caught between the two sides
For patients, disputes between hospitals and insurers can translate directly into higher out-of-pocket expenses.
In one case reviewed by Bloomberg, a Mumbai patient undergoing robot-assisted surgery expected the procedure to be covered under her health insurance. The insurer, however, declined to reimburse the portion of the bill attributed to the robotic component, leaving the patient to pay the difference.
The case reflects a broader challenge facing India’s healthcare financing system: determining which advanced treatments should be covered by insurance and how much patients should ultimately pay.
The Insurance Regulatory and Development Authority of India has introduced measures relating to cashless treatment and standardised authorisation procedures in an effort to address some of the friction between insurers, hospitals and policyholders.
Debate over regulation continues
The growing debate has also raised questions about whether tighter regulation of hospital prices could affect future investment.
EQT Group Chair Jean Eric Salata has warned that greater intervention in healthcare pricing could affect the investment environment and discourage further foreign investment.
Industry observers, however, argue that India faces a difficult balance between attracting capital needed to expand healthcare infrastructure and preventing medical treatment from becoming increasingly unaffordable.
The challenge is particularly significant for the country’s “missing middle” patients who may not qualify for government healthcare support but also lack the financial capacity to absorb rapidly increasing medical expenses.
As private capital continues to reshape India’s hospital industry, the central question is increasingly how the country can expand capacity and introduce advanced care while keeping healthcare financially accessible.




